CASE REPORT


Moxifloxacin Concentration and Proteomic Analysis of Aqueous Humor in Human Uveitis Associated with Oral Moxifloxacin Therapy



David M Hinkle1, *, Nicole A Kruh-Garcia2, Jonathan N Kruh3, Carolyn Broccardo4, Priyanka Doctor5, C Stephen Foster5, 6, 7
1 Department of Ophthalmology, University of Massachusetts Medical School, Worcester, Massachusetts, USA
2 Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA,
3 Jamaica Hospital Medical Center, Queens, New York, USA
4 Research Integrity and Compliance Review Office, Colorado State University, Colorado, USA
5 Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts, USA
6 Ocular Inflammation and Uveitis Foundation, Cambridge, Massachusetts, USA
7 Harvard Medical School, Boston, Massachusetts, USA


Article Metrics

CrossRef Citations:
5
Total Statistics:

Full-Text HTML Views: 4730
Abstract HTML Views: 2520
PDF Downloads: 949
ePub Downloads: 719
Total Views/Downloads: 8918
Unique Statistics:

Full-Text HTML Views: 1943
Abstract HTML Views: 1163
PDF Downloads: 611
ePub Downloads: 471
Total Views/Downloads: 4188



Creative Commons License
© 2017 Hinkle et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the UMass Memorial Eye Center, 281 Lincoln Street, Worcester, MA 01605, USA; Tel: 508-334-4629, Fax 508-334-4655, E-mail: david.hinkle@umassmemorial.org


Abstract

Purpose:

The aim was to report the aqueous humor moxifloxacin concentration and proteome profile of an individual with bilateral uveitis-like syndrome with pigment dispersion.

Methods:

Multiple reactions monitoring mass spectrometry quantified the aqueous concentration of moxifloxacin in the affected individual. Shotgun proteomic analysis performed via liquid chromatography tandem mass spectrometry (LC-MS/MS) defined the protein profile in the affected individual and unaffected control samples.

Results:

Moxifloxacin was present at higher than expected levels in aqueous humor 18 days following oral administration. One-third of the proteins were identified by significantly lower spectral counts in the aqueous of the individual with moxifloxacin associated uveitis compared to the unaffected control.

Conclusion:

Moxifloxacin was detected in aqueous humor 18 days following the completion of oral administration. These results suggest that moxifloxacin toxicity may be responsible for the uveitis-like syndrome with pigment dispersion syndrome induced by moxifloxacin therapy.